ALX Oncology Holdings Inc. announced that Dr. Pons will transition to the role of Chief Scientific Officer and remain President and both executives will remain members of the Board of Directors.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.52 USD | -0.99% | -10.98% | -3.09% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.16% | 764M | |
+8.84% | 114B | |
+11.47% | 104B | |
-12.75% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.14% | 17.89B | |
+8.33% | 14.28B | |
+34.89% | 12.55B |
- Stock Market
- Equities
- ALXO Stock
- News ALX Oncology Holdings Inc.
- ALX Oncology Holdings Inc. Appoints Dr. Jaume Pons Transitions to Chief Scientific Officer